WS17.02 Long-term efficacy of lumacaftor/ivacaftor (LUM/IVA) in children aged 2 through 5 years with cystic fibrosis (CF) homozygous for the F508del-CFTR mutation (F/F): a phase 2, open-label extension study. - Stahl, M.; Roehmel, J.; Eichinger, M.; Doellinger, F.; Naehrlich, L.; Kopp, M.V.; Dittrich, A.-M.; Sommerburg, O.; Ray, P.; Maniktala, A.; Duncan, M.E.; Xu, T.; et al. (Journal of Cystic Fibrosis, 2022)